BIOGEN INC. (BIIB) vs ELI LILLY & Co (LLY)
Side-by-side comparison from SEC filings: latest annual financials, insider activity and institutional ownership.
| Metric | BIIB | LLY |
|---|---|---|
| Sector | Health Care | Health Care |
| Latest fiscal year | FY2025 | FY2025 |
| Revenue | $9.89B | $65.18B |
| Revenue growth (YoY) | ▲ 2.2% | ▲ 44.7% |
| Net income | $1.29B | $20.64B |
| Gross margin | 75.7% | 83.0% |
| Diluted EPS | $8.79 | $22.95 |
| Insider net (6 mo) | +15.7K sh • 2 sells • 0 buys | −31.3K sh • 5 sells • 0 buys |
| Institutional owners | 42 | 51 |
| Institutional value held | $23.28B | $533.23B |
| Next earnings (est.) | Around Oct 29, 2026 | Around Oct 29, 2026 |
Figures from each company's SEC filings (latest reported fiscal year; fiscal calendars may differ). Next-earnings dates are estimates from historical filing patterns.
About BIOGEN INC. (BIIB)
Biogen is a global biopharmaceutical company dedicated to discovering, developing, and delivering therapies for serious and complex diseases, with a core focus on neurology, specialized immunology, and rare diseases. Read more →
About ELI LILLY & Co (LLY)
Eli Lilly and Company, incorporated in Indiana in 1901 and tracing its roots to a drug manufacturing business founded in 1876, operates as a single-segment human pharmaceutical company focused on discovering, developing, manufacturing, and marketing… Read more →
Source: SEC EDGAR.